Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$16.23
+1.2%
$16.34
$10.99
$18.92
$5.72B0.59495,748 shs629,177 shs
Glaukos Corporation stock logo
GKOS
Glaukos
$137.19
+0.6%
$116.05
$73.16
$146.75
$8.01B0.94792,839 shs490,221 shs
NovoCure Limited stock logo
NVCR
NovoCure
$18.10
-1.1%
$12.74
$9.82
$20.06
$2.12B0.91.96 million shs1.15 million shs
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
€17.59
-1.5%
€15.38
€12.89
€28.00
€5.33B0.75665,410 shs421,400 shs
10 Best Stocks to Own in 2026 Cover

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Spring 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
+1.12%+1.27%-2.33%-3.22%+36.80%
Glaukos Corporation stock logo
GKOS
Glaukos
+0.56%+1.11%+14.93%+28.55%+48.78%
NovoCure Limited stock logo
NVCR
NovoCure
-1.15%+9.70%+68.84%+44.34%-0.22%
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
-3.74%-7.60%+27.49%+12.71%-27.98%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$16.23
+1.2%
$16.34
$10.99
$18.92
$5.72B0.59495,748 shs629,177 shs
Glaukos Corporation stock logo
GKOS
Glaukos
$137.19
+0.6%
$116.05
$73.16
$146.75
$8.01B0.94792,839 shs490,221 shs
NovoCure Limited stock logo
NVCR
NovoCure
$18.10
-1.1%
$12.74
$9.82
$20.06
$2.12B0.91.96 million shs1.15 million shs
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
€17.59
-1.5%
€15.38
€12.89
€28.00
€5.33B0.75665,410 shs421,400 shs
10 Best Stocks to Own in 2026 Cover

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Spring 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
+1.12%+1.27%-2.33%-3.22%+36.80%
Glaukos Corporation stock logo
GKOS
Glaukos
+0.56%+1.11%+14.93%+28.55%+48.78%
NovoCure Limited stock logo
NVCR
NovoCure
-1.15%+9.70%+68.84%+44.34%-0.22%
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
-3.74%-7.60%+27.49%+12.71%-27.98%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
2.21
Hold$18.0811.45% Upside
Glaukos Corporation stock logo
GKOS
Glaukos
2.86
Moderate Buy$144.425.27% Upside
NovoCure Limited stock logo
NVCR
NovoCure
2.38
Hold$27.2950.75% Upside
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
2.40
HoldN/AN/A

Current Analyst Ratings Breakdown

Latest NVCR, GKOS, BLCO, and STVN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/4/2026
NovoCure Limited stock logo
NVCR
NovoCure
Boost Price TargetEqual Weight$13.50 ➝ $17.00
5/1/2026
NovoCure Limited stock logo
NVCR
NovoCure
Reiterated RatingOutperform
4/30/2026
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
Set Price Target$16.00
4/30/2026
Glaukos Corporation stock logo
GKOS
Glaukos
Set Price Target$170.00
4/30/2026
Glaukos Corporation stock logo
GKOS
Glaukos
Boost Price TargetBuy$135.00 ➝ $140.00
4/30/2026
Glaukos Corporation stock logo
GKOS
Glaukos
Boost Price TargetOverweight$120.00 ➝ $140.00
4/30/2026
Glaukos Corporation stock logo
GKOS
Glaukos
Boost Price TargetOverweight$135.00 ➝ $138.00
4/30/2026
Glaukos Corporation stock logo
GKOS
Glaukos
Boost Price TargetBuy$131.00 ➝ $141.00
4/30/2026
Glaukos Corporation stock logo
GKOS
Glaukos
Boost Price TargetBuy$127.00 ➝ $136.00
4/21/2026
Glaukos Corporation stock logo
GKOS
Glaukos
Reiterated RatingSell (D-)
4/21/2026
NovoCure Limited stock logo
NVCR
NovoCure
Reiterated RatingSell (E+)
(Data available from 5/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$5.10B1.13$1.69 per share9.61$18.09 per share0.90
Glaukos Corporation stock logo
GKOS
Glaukos
$507.44M15.88N/AN/A$11.42 per share12.01
NovoCure Limited stock logo
NVCR
NovoCure
$655.35M3.20N/AN/A$2.86 per share6.33
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
€1.34B3.97€0.85 per share20.68€5.92 per share2.97
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
-$360M-$0.62N/A15.020.49-4.21%3.60%1.69%7/29/2026 (Estimated)
Glaukos Corporation stock logo
GKOS
Glaukos
-$187.69M-$3.28N/A291.90N/A-34.34%-6.92%-5.25%7/29/2026 (Estimated)
NovoCure Limited stock logo
NVCR
NovoCure
-$136.23M-$1.53N/AN/AN/A-25.66%-50.82%-16.48%7/23/2026 (Estimated)
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
€158.21M€0.5929.8121.711.6811.76%10.27%6.08%N/A

Latest NVCR, GKOS, BLCO, and STVN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2026Q1 2026
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
€0.12€0.11-€0.01€0.10N/A€273.57 million
4/30/2026Q1 2026
NovoCure Limited stock logo
NVCR
NovoCure
-$0.5122-$0.62-$0.1078-$0.62$167.77 million$174.06 million
4/29/2026Q1 2026
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$0.06$0.08+$0.02-$0.20$1.22 billion$1.24 billion
4/29/2026Q1 2026
Glaukos Corporation stock logo
GKOS
Glaukos
-$0.30-$0.18+$0.12-$0.34$137.00 million$150.57 million
2/26/2026Q4 2025
NovoCure Limited stock logo
NVCR
NovoCure
-$0.41-$0.22+$0.19-$0.22$174.40 million$174.35 million
2/18/2026Q4 2025
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
$0.35$0.32-$0.03-$0.16$1.38 billion$1.41 billion
2/17/2026Q4 2025
Glaukos Corporation stock logo
GKOS
Glaukos
-$0.22-$0.28-$0.06-$2.32$132.16 million$143.12 million
2/14/2026Q4 2025
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
N/A€0.18N/A€0.17N/A€346.50 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
N/AN/AN/AN/AN/A
Glaukos Corporation stock logo
GKOS
Glaukos
N/AN/AN/AN/AN/A
NovoCure Limited stock logo
NVCR
NovoCure
N/AN/AN/AN/AN/A
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
N/AN/AN/AN/A1 Years
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
0.78
1.53
0.99
Glaukos Corporation stock logo
GKOS
Glaukos
0.10
5.43
4.73
NovoCure Limited stock logo
NVCR
NovoCure
0.71
2.90
2.70
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
0.21
1.63
1.11

Institutional Ownership

CompanyInstitutional Ownership
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
11.07%
Glaukos Corporation stock logo
GKOS
Glaukos
99.04%
NovoCure Limited stock logo
NVCR
NovoCure
84.61%
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
N/A

Insider Ownership

CompanyInsider Ownership
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
1.45%
Glaukos Corporation stock logo
GKOS
Glaukos
5.80%
NovoCure Limited stock logo
NVCR
NovoCure
5.52%
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
0.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bausch + Lomb Corporation stock logo
BLCO
Bausch + Lomb
13,000356.57 million351.40 millionOptionable
Glaukos Corporation stock logo
GKOS
Glaukos
1,09458.73 million55.33 millionOptionable
NovoCure Limited stock logo
NVCR
NovoCure
1,605115.82 million109.43 millionOptionable
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
6,010302.84 million300.72 millionOptionable

Recent News About These Companies

Stevanato Group SpA (STVN)
Here’s Why Stevanato Group Spa (STVN) Declined in Q1

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bausch + Lomb stock logo

Bausch + Lomb NYSE:BLCO

$16.23 +0.20 (+1.22%)
Closing price 05/13/2026 03:59 PM Eastern
Extended Trading
$16.00 -0.23 (-1.39%)
As of 05/13/2026 06:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.

Glaukos stock logo

Glaukos NYSE:GKOS

$137.19 +0.83 (+0.61%)
Closing price 05/13/2026 03:59 PM Eastern
Extended Trading
$137.36 +0.17 (+0.12%)
As of 05/13/2026 06:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

NovoCure stock logo

NovoCure NASDAQ:NVCR

$18.10 -0.21 (-1.15%)
Closing price 05/13/2026 04:00 PM Eastern
Extended Trading
$17.80 -0.30 (-1.65%)
As of 05:08 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

Stevanato Group stock logo

Stevanato Group NYSE:STVN

€17.59 -0.27 (-1.52%)
Closing price 05/13/2026 03:59 PM Eastern
Extended Trading
€17.92 +0.33 (+1.86%)
As of 05/13/2026 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.